fbpx

molecules of the month

zavegepant

CGRP receptor antagonist, first nasal spray

FDA-approved for acute migraines in adults

rational design based on known CGRP antagonists

FDA approval, March 10, 2023

Bristol Myers Squibb, NY / Pfizer, Inc., NY

zavegepant, CGRP receptor antagonist, first nasal spray, FDA-approved for acute migraines in adults, rational design based on known CGRP antagonists, FDA approval, March 10, 2023, BRISTOL MYERS SQUIBB, NY / PFIZER, INC., NY
8 mins read

The first approved CGRP receptor antagonist nasal spray for the treatment of migraine. Pfizer has announced the FDA-approval of zavegepant (ZAVZPRETTM, BHV-3500) for the treatment of acute migraine in adults based on positive Ph. II/III results. As the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for migraine treatment, zavegepant was statistically superior to placebo on the co-primary endpoints of ‘pain freedom’ and ‘freedom from most bothersome symptom’ at 2 hours after dosing (NCT04408794). This pivotal study also demonstrated pain relief as early as 15 minutes in a secondary endpoint, as compared to placebo. The rapid action for the intranasal delivery and the lack of needing to swallow a pill for relief for migraine patients, especially those…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: